文献速递乳房整形与再造

术前放化疗联合乳房切除术与乳房再造:临床、肿瘤学、重建与美学结局的系统综述

Pre-operative chemoradiotherapy followed by mastectomy and breast reconstruction-A systematic review of clinical, oncological, reconstructive and aesthetic outcomes.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2024-07-15

该系统综述检索截至2023年8月的数据库,纳入22篇文献共1258例患者,评估术前放疗或术前放化疗后行乳房切除术与即刻乳房再造的结局。局部区域复发率0-21.7%,总生存率82.0%-98.3%,皮瓣丢失或坏死率0-7.6%,再次手术率1.9%-35.3%。作者认为肿瘤学结局可接受,但多数研究的方法学质量低、偏倚风险高。

要点

  • 术前放疗或放化疗后乳房切除加即刻再造的局部区域复发率为0-21.7%,总生存率为82.0%-98.3%。
  • 皮瓣丢失或坏死率为0-7.6%,再次手术率为1.9%-35.3%。
  • 7项研究报告患者报告结局,多为「良好」或「优秀」。

核心结论

  • 术前放疗和术前放化疗后行乳房切除术与乳房再造产生可接受的肿瘤学结局,手术并发症率和重建结局在正常范围内,但多数现有研究方法学质量低且偏倚风险高。
  • 作者认为亟需一项在乳房再造背景下比较术前放疗与术后放疗的实用性随机试验来指导外科实践。

研究设计与样本

  • 系统综述,前瞻性注册检索Medline(Ovid)、EMBASE(Ovid)、EMCARE(Ovid)和CINAHL(EBSCO)数据库,检索时间为2023年8月。
  • 纳入22篇已发表文献(19篇期刊论文和3篇摘要),报告1258例患者结局,中位随访时间19.0-212.4个月。
  • 采用ROBINS-I评估偏倚风险,采用STROBE清单判定方法学质量。

主要发现

  • 20项研究中患者接受新辅助化疗。
  • 局部区域复发率范围为0-21.7%,总生存率范围为82.0%-98.3%。
  • 皮瓣丢失或坏死率范围为0-7.6%,再次手术率范围为1.9%-35.3%。
  • 7项研究报告患者报告结局,大多为「良好」或「优秀」。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 多数现有研究方法学质量低且偏倚风险高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pre-operative radiotherapy (PRT) and pre-operative chemoradiotherapy (PCRT) prior to mastectomy and immediate breast reconstruction for locally advanced breast cancer have the potential to reduce radiation late-effects and expedite oncologic treatment. Recent feasibility work indicates that PCRT is safe and technically possible. Here, we present a systematic review of currently available data on clinical, oncological, reconstructive and aesthetic outcomes. METHODS: A prospectively registered search of Medline (Ovid), EMBASE (Ovid), EMCARE (Ovid) and CINAHL (EBSCO) databases was performed in August 2023. Clinical, oncological, reconstructive and aesthetic outcomes were appraised with risk of bias (ROBINS-I) and methodological quality determined (STROBE checklist) for each study. RESULTS: Twenty-two published articles (19 journal articles and 3 abstracts) were identified reporting the outcomes of 1258 patients with median follow-up between 19.0-212.4 months. Patients received neoadjuvant chemotherapy in 20 studies. Rates of locoregional recurrence and overall survival ranged between 0-21.7% and 82.0%-98.3% respectively. Rates of flap loss or necrosis ranged from 0-7.6%. Rates of revisional procedures ranged between 1.9-35.3%. Patient-reported outcomes were reported in 7 studies and were mostly 'good' or 'excellent'. CONCLUSION: PRT and PCRT preceding mastectomy and breast reconstruction produce acceptable oncological outcomes with rates of surgical complication and reconstructive outcomes within normal limits, however, the majority of available studies are of low methodological quality and at high risk of bias. A pragmatic randomised trial comparing PRT versus PMRT in the setting of breast reconstruction is now urgently required to guide surgical practice.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Ward J, Ho K, Ike C, et al. Pre-operative chemoradiotherapy followed by mastectomy and breast reconstruction-A systematic review of clinical, oncological, reconstructive and aesthetic outcomes. J Plast Reconstr Aesthet Surg. 2024. PMID: 39106546. doi:10.1016/j.bjps.2024.07.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。